Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side).
Some good news from a clinical trial conducted by Eli Lilly (NYSE: LLY) boosted the share price of the pharmaceutical giant (by 0.5%) on Wednesday, leaving several rivals in the dust. These included device makers (NYSE: RMD), whose stock suffered a 6% blow, and AdaptHealth (NASDAQ: AHCO), with a nearly 2% decline.
Before market open, Eli Lilly announced that its molecule tirzepatide had achieved its primary endpoints in a set of phase 3 clinical trials. The studies aimed to judge its efficacy in treating obstructive sleep apnea (OSA), a common disorder in which people struggle to breathe properly while asleep.
Source Fool.com
Resmed Inc. Aktie
Rein positive Einschätzungen für Resmed Inc., nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Ein positives Kurspotenzial für Resmed Inc. ist gegeben, mit einem Kursziel von 215 € über dem aktuellen Kurs von 203.7 €.
